Onderneming Zentalis Pharmaceuticals, Inc.
Aandelen
ZNTL
US98943L1070
Biotechnologie & Medisch Onderzoek
Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
11,71 USD | +5,40% | +5,88% | -22,71% |
Vakgebied
Aantal werknemers: 124
Managers
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 55 | 01-07-20 | |
Cam Gallagher
FOU | Founder | 54 | 23-12-14 |
Mark Lackner
CTO | Chief Tech/Sci/R&D Officer | 56 | 17-10-22 |
Diana Hausman
CTO | Chief Tech/Sci/R&D Officer | 61 | 08-05-23 |
Kyle Rasbach
IRC | Investor Relations Contact | - | 19/01 |
Kimberly Freeman
PRN | Corporate Officer/Principal | - | 01-08-23 |
- | - | ||
Andrea Paul
LAW | General Counsel | 43 | 01-08-22 |
Meena Rao
LAW | General Counsel | - | - |
Corporate Officer/Principal | 61 | 01-03-20 |
Besturend
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Cam Gallagher
FOU | Founder | 54 | 23-12-14 |
Diana Hausman
CTO | Chief Tech/Sci/R&D Officer | 61 | 08-05-23 |
Karan Takhar
BRD | Director/Board Member | 32 | 01-12-17 |
Jan Skvarka
BRD | Director/Board Member | 57 | 12-09-22 |
Enoch K. Kariuki
BRD | Director/Board Member | 42 | 09-02-21 |
David Johnson
CHM | Chairman | 59 | 09-01-20 |
Chief Executive Officer | 55 | 01-07-20 |
Aandelenklasse
Stemming | Aantal | Vrij verhandelbaar | Bedrijfseigen aandelen | Drijvend Totaal | |
---|---|---|---|---|---|
Aandeel A | 1 | 71 013 233 | 67 981 965 ( 95,73 %) | 0 | 95,73 % |
Bedrijfsgegevens
Sector
Herzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-22,71% | 789 mln. | |
-1,43% | 103 mld. | |
+8,96% | 101 mld. | |
+4,40% | 23,07 mld. | |
-12,15% | 22,23 mld. | |
-4,36% | 18,05 mld. | |
-39,98% | 17,18 mld. | |
-10,04% | 16,94 mld. | |
+6,79% | 14,07 mld. | |
+38,61% | 12,35 mld. |
- Beurs
- Aandelen
- Koers ZNTL
- Onderneming Zentalis Pharmaceuticals, Inc.